INO (Inovio Pharmaceuticals) YoY EBITDA Growth: 61.91% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INO Inovio Pharmaceuticals Inc INO
39 GF Score
Price $1.43
GF Value $0.21
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Inovio Pharmaceuticals YoY EBITDA Growth?

Inovio Pharmaceuticals INO +5.54% 39 YoY EBITDA Growth is 61.91% as of Jun. 2026. GuruFocus rates INO with a GF Score™ of 39/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Inovio Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 61.91%.

Inovio Pharmaceuticals's EBITDA per Share for the three months ended in Jun. 2026 was $-0.22.

Inovio Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Inovio Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inovio Pharmaceuticals YoY EBITDA Growth Chart

Inovio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.29 20.06 56.84 34.91 54.32

Inovio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.22 1.04 111.77 51.19 61.91
INO
39GF Score
Inovio Pharmaceuticals Inc INO
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inovio Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Inovio Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-1.748--3.827)/ | -3.827 |
=54.32 %

Inovio Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.219--0.575)/ | -0.575 |
=61.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 61.91% mean?
Inovio Pharmaceuticals (INO) has a YoY EBITDA Growth of 61.91% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' YoY EBITDA Growth too high?
Inovio Pharmaceuticals' current YoY EBITDA Growth is 61.91%. Overall, Inovio Pharmaceuticals has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' YoY EBITDA Growth compare to HURA and VTVT?
Inovio Pharmaceuticals' YoY EBITDA Growth of 61.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current YoY EBITDA Growth is 61.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (INO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $1.43 — trading 578.6% above its estimated fair value. The current YoY EBITDA Growth is 61.91%. Inovio Pharmaceuticals' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Inovio Pharmaceuticals (INO), the current YoY EBITDA Growth is 61.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inovio Pharmaceuticals (INO) Overvalued in 2026?

Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued. The current stock price of $1.43 is trading 578.6% above its estimated GF Value™ of $0.21. GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INO:

  • YoY EBITDA Growth: 61.91%
  • GF Value™: $0.21 vs. price of $1.43 (578.6% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inovio Pharmaceuticals Business Description

Address 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
39GF Score

Get the complete analysis for INO

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.43
Price
$0.21
GF Value